Abnormal gene expression of proinflammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder

Bipolar Disorders

Volumn 17, Issue 6, 2015, Pages 636-644

  Pandey, Ghanshyam N ^a   Ren, Xinguo ^a   Rizavi, Hooriyah S ^a   Zhang, Hui ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

mRNA; Biomarkers; Bipolar illness; Cytokine receptors; Gene expression; Interleukin 1 receptors; Interleukin 6 receptors; Lymphocytes; Proinflammatory cytokines; Tumor necrosis factor receptors

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEMBRANE RECEPTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ARTICLE; ASIAN; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HAMILTON DEPRESSION RATING SCALE; HISPANIC; HOSPITAL PATIENT; HUMAN; LYMPHOCYTE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STRUCTURED INTERVIEW; BLOOD; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; STATISTICS;

ADULT; BIPOLAR DISORDER; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPHOCYTES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941024830     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12320     Document Type: Article

References (50)

1. Dantzer R, Aubert A, Bluthe R-M et al. Mechanisms of the behavioral effects of cytokines. In: Dantzer R, Wollman EE, Yirmiya R eds. Cytokines, Stress and Depression. New York, NY: Kluwer Academic/Plenum Publishers, 1999: 83-105.
2. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001; 933: 222-234.
3. Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-652.
4. Du J, Gould TD, Manji HK. Neurotrophic signaling in mood disorders. In: Finkel T, Gutkind JS eds. Signal Transduction and Human Disease. Hoboken, NJ: John Wiley & Sons Inc, 2003: 411-447.
5. Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89: 356-362.
6. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47: 1119-1133.
7. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144: 16-27.
8. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 15-25.
9. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep 2013; 15: 387.
10. Barbosa IG, Huguet RB, Mendonca VA et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011; 261: 139-143.
11. Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-309.
12. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263-267.
13. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009; 23: 1079-1082.
14. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664-675.
15. Padmos RC, Hillegers MH, Knijff EM et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008; 65: 395-407.
16. Altman EG, Hedeker DR, Janicak PG, Peterson JL, Davis JM. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry 1994; 36: 124-134.
17. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
18. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
19. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991; 5: 2567-2574.
20. Dinarello CA. Cytokines as mediators in the pathogenesis of septic shock. Curr Top Microbiol Immunol 1996; 216: 133-165.
21. McMahan CJ, Slack JL, Mosley B et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991; 10: 2821-2832.
22. Sims JE, Acres RB, Grubin CE et al. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci USA 1989; 86: 8946-8950.
23. Kuno K, Matsushima K. The IL-1 receptor signaling pathway. J Leukoc Biol 1994; 56: 542-547.
24. Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-340.
25. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-1451.
26. Rose-John S. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003; 50: 603-611.
27. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-236.
28. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-1635.
29. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005; 90: 663-670.
30. Kronke M, Schutze S, Scheurich P et al. Tumour necrosis factor signal transduction. Cell Signal 1990; 2: 1-8.
31. Rothe J, Gehr G, Loetscher H, Lesslauer W. Tumor necrosis factor receptors - structure and function. Immunol Res 1992; 11: 81-90.
32. Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen Physiol Biophys 2007; 26: 159-167.
33. Cortez-Cooper M, Meaders E, Stallings J et al. Soluble TNF and IL-6 receptors: indicators of vascular health in women without cardiovascular disease. Vasc Med 2013; 18: 282-289.
34. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25: 1206-1213.
35. Ortiz-Dominguez A, Hernandez ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9: 596-602.
36. Hope S, Dieset I, Agartz I et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45: 1608-1616.
37. Hope S, Melle I, Aukrust P et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009; 11: 726-734.
38. Hope S, Ueland T, Steen NE et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013; 145: 36-42.
39. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110-116.
40. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156-161.
41. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1366-1371.
42. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397-403.
43. Wachter H, Fuchs D, Hausen A et al. Neopterin: Biochemistry, Methods, and Clinical Application. Berlin, NY: Walter de Gruyter, 1992.
44. Schobitz B, De Kloet ER, Holsboer F. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Progr Neurobiol 1994; 44: 397-432.
45. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I: expression and recognition. Trends Neurosci 1995; 18: 83-88.
46. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
47. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C. Cytokine signals propagate through the brain. Mol Psychiatry 2000; 5: 604-615.
48. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Progr Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
49. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15: 384-392.
50. Pandey GN, Rizavi HS, Ren X et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 2012; 46: 57-63.